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Law and Genetics

Paul Lanza

Bridging the Gap Between Doctor and Patient Utilization and Understanding of BRCA1/2
Mutation Testing
I. Introduction
With the early detection of deadly diseases in mind, genetic testing is growing more and
more important in the practice of medicine. Genetic testing has evolved greatly since its rise in
utility over the past two decades. As in all forms of medical screening, however, doctors must
carefully weigh the benefits and risks in referring patients for genetic testing. In 2005, the US
Preventive Services Task Force (USPSTF) issued a recommendation against routine BRCA
genetic testing for breast and ovarian cancer on the basis that only a small population of women
are actually genetically predisposed to the harmful genetic mutations associated with these types
of cancer.1 According to the USPSTF, risks such as false-positive and false-negative results and
other psychological and behavioral outcomes greatly outweigh any potential benefit to routine
screening for women without specific family history patterns.2 Despite the USPSTF
recommendation, 89% of primary care physicians have indicated needs for more clinical
guidelines for genetic testing for cancer susceptibility.3 One problem seems to be that, although
doctors recognize the growing importance of genetics regardless of their field of medicine, many
feel they have inadequate resources to meet the demands of their practice. Another problem is
that patients may be exacerbating the issue by overestimating their risks for BRCA mutations and
needlessly requesting testing themselves.
This paper will explore the issues related to doctor and patient utilization and
understanding of clinical guidelines to genetic predisposition testing using the case study of the
1

U.S. Preventive Servs. Task Force, Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian
Cancer Susceptibility: Recommendation Statement, 143 ANNALS INTERNAL MED. 355 (2005), http://www.uspreven
tiveservicestaskforce.org/uspstf05/brcagen/brcagenrs.pdf [hereinafter USPSTF].
2
Id.
3
See Robert Klitzman, Attitudes and Practices Among Internists Concerning Genetic Testing, 22 J. GENETIC
COUNSELING 90, 91 (2013).
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USPSTF recommendations for BRCA mutation testing. Part II will discuss the BRCA1/2 genes
and mutations, the various risk assessment tools and methods that are used as screening devices,
and the DNA sequencing test. Part III will discuss the report used by the USPSTF in making its
recommendation. Part IV will discuss the issues related to physician and patient use and
understanding of genetic screening for cancer susceptibility. Finally, Part V will contain my
recommendations for how to address the issues raised in Part IV.
II. The BRCA 1/2 Genes, Mutations, and Tests
A. The BRCA1/2 Genes and Mutations
Doctors and geneticists have identified two genes related to breast and ovarian cancer in
women: BRCA1 and BRCA2. The names BRCA1 and BRCA2, respectively, stand for breast
cancer susceptibility gene 1 and breast cancer susceptibility gene 2.4 Although the functions of
BRCA1 and BRCA2 are interrelated, their structures are quite different.
BRCA1 is a tumor-suppressor gene that is important in regulating the growth of breast
epithelial cells.5 As a tumor-suppressor gene, the BRCA1 gene produces a protein that helps
prevent cells from growing and dividing too rapidly or in an uncontrolled way.6 The human
BRCA1 gene is located on the long (q) arm of chromosome 17 at region 2 band 1, from base pair
41,196,312 to base pair 41,277,500.7 The BRCA1 gene was first identified by the King
Laboratory at UC Berkeley in 1990.8 Later, scientists at the University of Utah, National Institute
of Environmental Health Sciences (NIEHS), and Myriad Genetics cloned the gene for the first

See Nat’l Cancer Inst., BRCA1 & BRCA2: Cancer Risk and Genetic Testing,
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA (reviewed May 29, 2009).
5
See J. Fergus Couch ET AL., BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast
Cancer, 336 NEW ENG. J. MED. 1409, 1409 (1997).
6
See Genetics Home Reference, BRCA1, http://ghr.nlm.nih.gov/gene/BRCA1 (reviewed Aug. 2007) [hereinafter
Genetics Home Reference, BRCA1].
7
See J.A. Duncan ET AL., BRCA1 & BRCA2 Proteins: Roles in Health and Disease. UNIV. DEP’T SURGERY,
GLASGOW ROYAL INFIRMARY (1998).
8
See JM Hall ET AL., Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21, 250 SCIENCE (1990).
4
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time in 1994.9 It is critical for the repair of double-strand DNA breaks (DSBs) and interstrand
crosslinks (ICLs) by homologous recombination (HR).10 These breaks can be caused by natural
and medical radiation or other environmental exposures, and also occur when chromosome
exchange genetic material in preparation for cell division.11 Researchers believe that the BRCA1
protein also regulates the activity of other genes and plays a critical role in embryonic
development.12
There are more than 1,000 mutations in the BRCA1 gene.13 The majority of these
mutations lead to the production of an abnormally short version of the BRCA1 protein, or prevent
any protein from being made from one copy of the gene.14 The most common mutations are a
deletion of adenine and guanine (185delAG) and an insertion of cytosine (5382insC).15 A
defective or missing BRCA1 protein is unable to help repair damaged DNA or fix mutations that
occur in other genes. When these defects accumulate, the uncontrolled growth and division of
cells can form a tumor.16 BRCA1 mutations account for 45 percent of hereditary cases of breast
cancer and 80 to 90 percent of hereditary cases of combined breast and ovarian cancer.17
Harmful BRCA1 mutations may also increase a woman’s risk of cervical, uterine, pancreatic, and
colon cancer.18

9

See Hall, supra note 8.
See Shane R. Stecklein ET AL., BRCA1 and HSP90 Cooperate in Homologous and Non-Homologous DNA
Double-Strand-Break Repair and G2/M Checkpoint Activation, 109 PROC. NAT’L ACAD. SCI. 13650, 13651 (2012).
11
See Genetics Home Reference, BRCA1, supra note 6.
12
Id.
13
Id.
14
Id.
15
See Couch, supra note 5 at 1409.
16
See Genetics Home Reference, BRCA1, supra note 6.
17
See Couch, supra note 5 at 1409.
18
See Nat’l Cancer Inst., supra note 4.
10
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The BRCA2 gene also belongs to the tumor-suppressor gene family.19 Like the BRCA1, it
is similarly important for the regulation of cell growth and division.20 It is located on the long (q)
arm of chromosome 13 at position region 12 band 3 from base pair 32,889,616 to 32,973,808.21
The BRCA2 gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC
Research and Development Limited Partnership, and University of Pennsylvania.22 Research
shows that the BRCA2 protein may also help regulate cytokinesis, which is the step in cell
division when the cytoplasm divides to form two separate cells.23 There are approximately 800
different mutations associated with the BRCA2 gene.24 Many of the mutations disrupt protein
production from one copy of the gene in each cell, resulting in an abnormally small,
nonfunctional version of the BRCA2 protein.25 Harmful BRCA2 mutations may additionally
increase the risk of pancreatic cancer, stomach cancer, gallbladder and bile duct cancer, and
melanoma.26
The next two sections will explain how patients are tested for BRCA1/2 mutation
susceptibility. There are two methods: risk assessment testing and DNA sequencing. Risk
assessment testing is typically completed first to determine whether DNA sequencing is
warranted.
B. Risk Assessment Testing for BRCA1/2 Mutation Among Women
There are two important types of testing related to breast and ovarian cancer
susceptibility: risk assessment testing and DNA sequencing. Risk assessment is important

19

See Genetics Home Reference, BRCA2, http://ghr.nlm.nih.gov/gene/BRCA2 (reviewed Aug. 2007) [hereinafter
Genetics Home Reference, BRCA2].
20
Id.
21
See Duncan, supra note 7.
22
Id.
23
See Nat’l Cancer Inst., supra note 4.
24
Id.
25
Id.
26
Id.
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because guidelines recommend testing for mutations only when an individual has personal or
family history features suggestive of inherited cancer susceptibility.27 Although the BRCA1/2
mutations can occur in anyone, certain specific family history patterns are associated with an
increased risk for mutation. For example, specific BRCA mutations are clustered among certain
ethnic groups, such as Ashkenazi Jews, and among families in the Netherlands, Iceland and
Sweden.28 For non-Ashkenazi Jewish women, patterns associated with an increased risk for
BRCA1/2 mutation include two first-degree relatives with breast cancer, one of whom received
the diagnosis at age 50 years or younger; a combination of three or more first- or second-degree
relatives with breast cancer regardless of age at diagnosis; a combination of both breast and
ovarian cancer among first- and second-degree relatives; a first-degree relative with bilateral
breast cancer; a combination of two or more first- or second-degree relatives with ovarian cancer
regardless of age at diagnosis; a first- or second-degree relative with both breast and ovarian
cancer at any age; and a history of breast cancer in a male relative.29 About two percent of adult
women in the general population have an increased-risk family history as defined above.30 Those
women that do not fall into any of the increased family history patterns have a low probability of
having a deleterious mutation in BRCA1 or BRCA2 genes.31 It is important to remember that
developing breast or ovarian cancer does not necessarily automatically follow from a BRCA
mutation. The probability of developing breast or ovarian cancer by age 70 years in a woman

27

See HD Nelson ET AL., Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer
Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force, ANNALS INTERNAL MED.
(2005), http://www.ncbi.nlm.nih.gov/books/NBK43308.
28
See USPSTF, supra note 1.
29
Id.
30
Id.
31
Id.
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who has a clinically important BRCA mutation, is estimated to be 35 percent to 84 percent for
breast cancer and 10 to 50 percent for ovarian cancer.32
There are several different risk tools for predicting risk for deleterious BRCA1/2
mutations. The four most widely used risk tools include the Myriad Genetic Laboratories model,
the Couch model, BRCAPRO, and the Tyrer model.33 Unfortunately, no studies of their
effectiveness in a primary care screening population are available, as much of the data from these
models are from women with existing cancer, and their applicability to asymptomatic, cancerfree women in the general population is unknown.34
There are two Myriad Genetic Laboratories models. The first model is used exclusively
to predict risk for BRCA1 mutation and is based on a population of women with either earlyonset breast cancer or ovarian cancer, or with a family history of breast or ovarian cancer.35 This
logistic regression model also takes into account bilateral breast cancer, age of diagnosis, and
Ashkenazi Jewish ancestry, and is not dependent on affected relatives.36 The second model
predicts risk for both BRCA1 and BRCA2 mutations and is based on a population of women with
breast cancer under age 50 or ovarian cancer who have at least one first- or second-degree
relative with early breast and ovarian cancer.37 This model considers bilateral breast cancer,
concurrent breast and ovarian cancer, and breast cancer under age 40.38
The second risk assessment tool is the Couch Model. This model is based on logistic
regression of data from a population of women with breast cancer and a family history of breast

32

See USPSTF, supra note 1.
See Nelson, supra note 27.
34
See USPSTF, supra note 1.
35
See D Shattuck-Eidens ET AL., BRCA1 Sequence Analysis in Women at High Risk for Susceptibility Mutations.
Risk Factor Analysis and Implications for Genetic Testing, 278 J. AM. MED. ASS’N 1242, 1245 (1997).
36
Id.
37
Id.
38
Id.
33
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and/or ovarian cancer, and predicts risk for BRCA1 mutation.39 The original model determined
mutations by conformation sensitive gel electrophoresis (CSGE) rather than DNA full
sequencing, which potentially underestimated mutation prevalence.40 The refined model includes
both BRCA1 and BRCA2 mutations using DNA full sequencing.41 This model does not require
the individual to have breast or ovarian cancer, however the family must have more than two
cases of breast cancer.42 Some of the predictors used in the Couch model include the number of
women diagnosed with breast cancer under age 50, concurrent breast and ovarian cancer, ovarian
cancer, male breast cancer, and Ashkenazi Jewish ancestry.43
The third risk assessment tool is the BRCAPRO model. The BRCAPRO model is a
Bayesian model that provides estimates of risk for BRCA1 and BRCA2 mutations.44 It has been
validated in populations of women with increased prevalence of specific mutations.45 In
BRCAPRO, the individual may or may not have breast or ovarian cancer.46 It considers factors
such as current age, age at diagnosis, bilateral breast cancer, concurrent breast and ovarian
cancer, all first- and second-degree relatives with and without cancer, males with breast cancer,
and Ashkenazi Jewish ancestry.47 It includes information on both affected and unaffected
relatives.48

39

See Couch, supra note 5 at 1411.
See Nelson, supra note 27.
41
See MA Blackwood ET AL., Predicted Probability of Breast Cancer Susceptibility Gene Mutations. 69 BREAST
CANCER RESEARCH AND TREATMENT (2001).
42
See Nelson, supra note 27.
43
Id.
44
See DA Berry ET AL., Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on
Family History, 89 J. NAT’L CANCER INST. 227, 229 (1997) [hereinafter Berry, Probability].
45
See DA Berry DA ET AL., BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and
Prevalence of Other Breast Cancer Susceptibility Genes, 20 J. CLINICAL ONCOLOGY 2701, 2702 (2002) [hereinafter
Berry, BRCAPRO].
46
See Nelson, supra note 27.
47
Id.
48
Id.
40
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The fourth model is the Tyrer model. This model provides a comprehensive risk estimate
using personal risk factors in combination with a genetic analysis.49 Similar to the Couch model
and BRCAPRO, the individual is not required to have breast or ovarian cancer.50 The model
includes personal risk factors such as current age, age at menarche, parity, age at first childbirth,
age at menopause, atypical hyperplasia, lobular carcinoma in situ, height, and body mass index
(BMI).51 As part of the genetic analysis, the model incorporates the high-risk, high-penetrance
BRCA1 and BRCA2 germline mutations with the addition of a low-penetrance gene.52 The lowpenetrance gene is included as a stand-in to account for the effect of all other unidentified
genes.53 The Tyrer Model is run through a computer program that is still not yet widely
distributed.54 The program uses segregation analysis techniques based on Bayes’ theorem to
determine the risk of BRCA1/2 mutations.55
As mentioned supra, the effectiveness of risk assessment tools such as the Myriad
Genetic Laboratories model, Couch model, BRCAPRO, and Tyrer model is unknown in a
primary care setting. Primary care physicians do, however, have access to three other risk
assessment tools for potential BRCA1/2 mutations. These tools are the Family History Risk
Assessment Tool (FHAT), the Manchester scoring system, and the Risk Assessment in Genetics
(RAGs) tool.56 Using these risk tools, primary care physicians can manage recommendations of

49

See J Tyrer ET AL., A Breast Cancer Prediction Model Incorporating Familial and Personal Risk Factors,
23 STATISTICS IN MEDICINE 1111, 1112 (2004).
50
See Nelson, supra note 27.
51
Id.
52
Id.
53
Id.
54
Id.
55
Id.
56
See CA Gilpin ET AL., A Preliminary Validation of a Family History Assessment Form to Select Women at Risk
for Breast or Ovarian Cancer for Referral to a Genetics Center, 58 CLINICAL GENETICS 2999, 3002 (2000).
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reassurance, referral to a breast clinic, or referral to a geneticist on the basis of the patient’s
respective risk categories.57
The FHAT helps clinicians select patients for referral to genetic counseling.58 This tool
uses a point system based on the number of relatives, third-degree or closer, diagnosed with
breast, ovarian, colon, or prostate cancer, and the relationship to the individual being evaluated,
age at diagnosis, and type and number of primary cancers.59 If a patient receives a score of 10
points or higher, then the doctor should refer her for genetic counseling.60 The sensitivity and
specificity of FHAT for a clinically significant BRCA1 or BRCA2 mutation were 94% and 51%,
respectively.61
The Manchester scoring system is a risk assessment tool developed in the U.K. to predict
deleterious BRCA1/2 mutations at the 10% likelihood level.62 Similar to the FHAT, the
Manchester scoring system assigns points depending on the type of cancer (breast, ovarian,
pancreatic, or prostate) affected family members, and age at diagnosis and provide scores for
BRCA1 and BRCA2 mutations separately.63 The Manchester model had 87% sensitivity and 66%
specificity for combined BRCA1 and BRCA2 mutations, which compared well with other models
tested.64
The Risk Assessment in Genetics (RAGs) tool is a computer program used to assess and
manage family breast and ovarian cancer in primary care settings.65 Using information about the
patient and relatives, including family history and the age of the presenting patient, RAGs
57

See USPSTF, supra note 1.
See Gilpin, supra note 56.
59
See Nelson, supra note 27.
60
Id.
61
Id.
62
See DG Evans ET AL., A New Scoring System for the Chances of Identifying a BRCA 1/2 Mutation Outperforms
Existing Models Including BRCAPRO, 41 J. MED. GENETICS 474 (2004).
63
See Nelson, supra note 27.
64
Id.
65
Id.
58
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generates categories of risk for breast and ovarian cancer, referral guidelines, and suggests
appropriate management. This tool assigns one of three risk levels: low (<10% risk of having a
clinically significant BRCA1/2 mutation), in which the patient is reassured and managed in
primary care; moderate (10-25% risk), in which the patient is referred to a breast clinic; and high
(>25% risk, in which the patient is referred to a clinical geneticist.66 Tested against other primary
care risk assessment tools, RAGs resulted in significantly more appropriate management
decisions and more accurate pedigrees, and was the preferred approach.67 Moreover, RAGs took
on average 178 seconds to administer.68
In sum, primary care physicians have numerous risk assessment tools at their disposal in
order to determine a patient’s risk for a genetic predisposition to a BRCA1/2 mutation. Using
these tools, a physician will classify women according to the risk group that they fall in. In the
case of a patient falling into a low or moderate-risk group, a doctor will recommend against
further testing. Alternatively, if the patient falls into a high-risk category, further testing should
be recommended. Women who are classified as being at high-risk for a BRCA1/2 mutation go on
to DNA sequencing testing, which is described in the next section.
C. DNA Sequencing Tests for the BRCA1/2 Mutations
The second type of testing for susceptibility to breast and ovarian cancer is DNA
sequencing for clinically significant BRCA1/2 mutations. Guidelines for testing recommend
DNA sequencing only for women in the high-risk category as defined above.69 Nevertheless, any
woman could request testing on her own regardless of her personal risk factor. Several clinical
laboratories in the United States test for specific mutations or sequence-specific exons.

66

See Nelson, supra note 27.
Id.
68
Id.
69
Id.
67
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Individuals without linkages to others with known mutations undergo direct DNA sequencing. In
these cases, guidelines recommend that testing begin with a relative who has known breast or
ovarian cancer to determine whether a clinically significant mutation is segregating in the
family.70 Myriad Genetic Laboratories provides direct DNA sequencing in the United States and
reports analytic sensitivity and specificity exceeding 99 percent.71 72 Test results include not only
positive (denoting a deleterious mutation) and negative (no mutation found) interpretations, but
also variants of uncertain clinical significance.73 Approximately 13 percent of all those tested
will have results with uncertain clinical significance.74 For testing, a small sample of blood must
be drawn or an oral rinse sample taken.75 DNA sequencing can take up to two weeks for
results.76 DNA sequencing tests can cost several hundred dollars, although some insurance
companies will cover the cost.77
This section discussed the BRCA1/2 genes and mutations and also the two methods for
screening for the mutations. Now, it is time to turn to the USPSTF recommendations and the
study that provided the foundation for those recommendations. The study relied on the answers
to five key questions to issue its conclusions for the USPSTF to review. Those key questions are
answers are discussed in the next section.
III. Analysis of the Nelson Study, 2005 US Preventive Services Task Force
Recommendation, and Recommendations of Other Professional Medical Groups
70

See Nelson, supra note 27.
Id.
72
Analytic sensitivity refers to the proportion of actual positives results that are correctly identified. This is
sometimes called the true positive value. For example, sensitivity refers to the percentage of sick people who are
correctly identified as having the condition. Specificity, however, measures the proportion of negative that are
correctly identified. For example, the specificity of a study would show the percentage of healthy people who are
correctly identified as not having the condition. This is sometimes called the true negative value.
73
See Nelson, supra note 27.
74
Id.
75
See Myriad Genetics, Genetic Testing Process, http://www.myriad.com/physicians/genetic-testing/genetic-testingprocess-2/ (last visited May 5, 2103).
76
Id.
77
See Nelson, supra note 27.
71
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A. Discussion of the Nelson Study, Five Key Questions, and USPSTF Recommendations
Concerned with the growing public interest in BRCA testing, despite the rarity of
mutations in the general population, the USPSTF commissioned a research group to determine
the benefits and harms of screening for inherited breast and ovarian cancer susceptibility in the
general population of women without cancer presenting for primary health care in the United
States.78 The study was published in 2005 in the ANNALS OF INTERNAL MEDICINE. The research
was funded by the Centers for Disease Control and Prevention under a contract with the Agency
for Healthcare Research and Quality.79 The ultimate recommendations issued by the USPSTF
were based on the responses to five key questions investigated in the Nelson study.
The first key question is whether risk assessment and BRCA mutation testing leads to a
reduction in the in the incidence of breast and ovarian cancer and cause-specific or all-cause
mortality. The research group found that no studies demonstrate that a screening approach
consisting of risk assessment in a primary care setting followed by BRCA mutation testing and
preventive interventions for appropriate candidates ultimately reduces the incidence of breast and
ovarian cancer and cause-specific or all-cause mortality.80
The second key question investigates how well clinicians in a primary care setting select
candidates BRCA mutation testing using risk assessment. The Nelson study began by identifying
three methods used by primary care physicians to complete risk assessment for cancer
susceptibility. The most important method is a determination of family history. Decisions about
referral, testing, and prevention interventions are often based on self-reports of family histories
that include types of cancers, relationships within the family, and ages of onset. Appropriate
78

See Nelson, supra note 27. The research was conducted by Heidi D. Nelson, MD, MPH; Laurie Hoyt Huffman,
MS; Rongwei Fu, PhD; and Emily L. Harris, PhD, MPH. The report published by Nelson, Huffman, Fu, and Harris
will hereinafter be referred to as the Nelson study.
79
See Nelson, supra note 27.
80
Id.
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decisions rely on family histories that are accurately reported by women and correctly obtained
by clinicians.81 One study determined the sensitivity and specificity of a family history of breast
or ovarian cancer in first-degree relatives reported by individuals without cancer to be more
reliable with respect to breast cancer than ovarian cancer. Specifically, the study found a
sensitivity of 82 percent and specificity of 91 percent with respect to breast cancer, but 50
percent and 99 percent, respectively, for ovarian cancer.82
Risk assessment tools are the second method utilized to determine how well primary care
physicians select candidates for BRCA mutation testing. As discussed above, there are several
different tools and methods available to primary care physicians such as the Myriad Genetics
model, the Couch model, BRCAPRO, the Tyrer model, and others. Their effectiveness in
screening the general population is unknown.
Finally, the third method is referral guidelines. In order to help primary care physicians
identify women at potentially increased risk for BRCA mutations, health maintenance
organizations, professional organizations, cancer programs, state and national health programs,
and investigators develop referral guidelines. Most include questions about personal and family
history of BRCA mutations, breast and ovarian cancer, age of diagnosis, bilateral breast cancer,
and Ashkenazi Jewish heritage.83 Moreover, most guidelines are not intended to lead directly to
testing, but instead lead to a referral for more extensive genetic evaluation and counseling.84 The
effectiveness of referral guidelines is still unknown as no studies have been conducted to
measure the efficacy of the guidelines.85

81

See Nelson, supra note 27.
RA Kerber & ML Slattery, Comparison of Self-Reported and Database-Linked Family History of Cancer Data in
a Case-Control Study, 146 AM. J. EPIDEMIOLOGY 244, 245 (1997).
83
See Nelson, supra note 27.
84
Id.
85
Id.
82
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Thus, the Nelson study determined that primary care physicians use three different
methods in selecting candidates for BRCA mutation testing: family history, risk assessment tools,
and referral guidelines. Despite the fact that primary care physicians have a multitude of
different resources at their fingertips, it is generally unknown how effective these methods are in
the general population among asymptomatic women. Moreover, the use of these methods will
increase the amount of time doctors will have to spend with each patient, something doctors may
be unwilling to do if they must see a high volume of patients each day. Still, risk assessment,
particularly through a collection of family history information, may be a cheap and effective way
to conduct risk assessment because many primary care physicians collect family history
information as part of their routine exam. Overall, more research needs to be done on the
effectiveness of these three methods in the general population among asymptomatic women.
The third key question explores the benefits of genetic counseling before testing. On the
one hand, there are no studies that determine the physical benefits of genetic counseling before
testing. That is to say that no studies describe cancer or mortality outcomes related to genetic
counseling.86 On the other hand, there are ten studies that measure the psychological and
behavioral outcomes associated with genetic counseling before testing.87 These studies
specifically looked to measure the impact of genetic counseling on breast cancer worry, anxiety,

86

See Nelson, supra note 27.
See DJ Bowen, Breast Cancer Risk Counseling Improves Women’s Functioning, 53 PATIENT EDUC. COUNSELING
79, 81 (2004); DJ Bowen, Effects of Risk Counseling on Interest in Breast Cancer Genetic Testing for Lower Risk
Women, 4 GENETICS MED. 359, 362 (2002); W Burke, Genetic Counseling for Women with an Intermediate Family
History of Breast Cancer, 90 AM. J. MED. GENETICS 361, 363 (2000); A Cull, The Use of Videotaped Information in
Cancer Genetic Counseling, 77 BRIT. J. CANCER 830, 831 (2000); C Lerman, Racial Differences in Testing
Motivation and Psychological Distress Following Pretest Education for BRCA1 Gene Testing, 8 CANCER
EPIDEMIOLOGY BIOMARKERS PREV. 361, 362 (1999); C Lerman, A Randomized Trial of Breast Cancer Risk
Counseling, 15 HEALTH PSYCHOL. 75, 75 (1996); C Lerman, Effects of Individualized Breast Cancer Risk
Counseling, 87 J. NAT’L CANCER INST. 286, 288 (1995); E Lobb, The Use of Audiotapes in Consultations with
Women from High Risk Breast Cancer Families. 39 J. MED. GENETICS 697, 698 (2002); M Watson, Family History
of Breast Cancer. 35 J. MED. GENETICS 731, 732 (1998); MJ Green, Effect of a Computer-Based Decision Aid on
Knowledge, Perceptions, and Intentions About Genetic Testing for Breast Cancer Susceptibility, 292 J. AM. MED.
ASS’N 442, 444 (2004).
87
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depression, perception of cancer risk, and intent to participate in genetic testing. Nine of the ten
studies reported a decrease in psychological distress or no effect after counseling.88 Five trials
showed increased accuracy of perception of cancer risk among women who received genetic
counseling.89 One study showed less accurate risk perception after genetic counseling and one
had mixed results.90 In conclusion, there is no data that suggests genetic counseling before
testing has any physical benefit; however, a majority of studies report either a positive
psychological impact or no impact at all.
The fourth key questions measures how well BRCA mutation testing predicts risk for
breast or ovarian cancer among women with family histories predicting an average, moderate, or
high risk for a deleterious mutation. This key question incorporates two issues. First, it is
important to define which women qualify as either possessing an average, moderate or high risk
for a deleterious mutation. A woman with an average risk has no first-degree relatives and no
more than one second-degree relative on each side of the family with breast or ovarian cancer.91
A woman has a moderate risk if she has one first-degree relative or two second-degree relatives
on the same side of the family with breast or ovarian cancer.92 Lastly, a woman has a high risk if
she has at least two first-degree relatives with breast or ovarian cancer.93
The second issue is addressing how to measure the efficacy of BRCA mutation testing in
identifying risk for breast and ovarian cancer. One method is to look at the prevalence of BRCA1/2
mutations in women. Nelson’s study estimated the prevalence of BRCA1 and BRCA2 mutations in
women at average risk could be as high as .24%, moderate risk to be .24% to 3.4%, and high risk to

88

See Nelson, supra note 27.
Id.
90
Id.
91
Id.
92
Id.
93
Id.
89
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be 8.7% and above.94 Other models estimate the prevalence of deleterious mutation in the nonJewish US population to be about 1 in 300 to 500 persons.95 Still another model estimates the
prevalence among women with a strong family history of cancer to be 8.7%.96 These numbers are
remarkable in that they show just how rarely BRCA1/2 mutations occur in average or moderate risk
groups.
The second method for determining how well BRCA mutation testing predicts risk for
breast and ovarian cancer is to look at the penetrance. Penetrance is the probability of developing
breast or ovarian cancer among women who have a clinically significant BRCA1 or BRCA2
mutation.97 For breast cancer, Nelson’s study estimates BRCA1 penetrance to age 75 years are
68.8% in average-risk groups; 49.9% in moderate-risk groups, and 60.5% in high-risk groups.98
BRCA2 penetrance estimates are only available for the high-risk group: 53.0%.99 For ovarian
cancer, BRCA1 penetrance estimates to age 75 years are 29.2% in average-risk groups, 55.1% in
moderate-risk groups, and 26.1% in high-risk groups. BRCA2 penetrance estimates for ovarian
cancer are 34.2%, 27.0%, and 6.4%.100 These numbers show that a woman with a deleterious
mutation does not automatically develop breast or ovarian cancer. In addition, there does not
seem to be an obvious correlation between either a BRCA1 or BRCA2 mutation and breast or
ovarian cancer across women in different risk groups.
The fifth key question explores the adverse effects of risk assessment, genetic counseling,
and testing. This is an important step in order to way both the benefits and Two important

94

Id.
Anglian Breast Cancer Study Group, Prevalence and Penetrance of BRCA1 and BRCA2 Mutations in a
Population-Based Series of Breast Cancer Cases, 83 BRIT. J. CANCER 1301, 1302 (2000).
96
TS Frank, Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: Analysis of
10,000 Individuals, 20 J. CLINICAL ONCOLOGY 1480, 1483 (2000).
97
See Nelson, supra note 27.
98
Id.
99
Id.
100
Id.
95
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adverse effects of risk assessment, genetic counseling, and testing are false-positive and falsenegative results that could occur at each step of screening for a BRCA1/2 mutation. Falsepositive and false-negative results are especially troublesome because that can lead to
inappropriate reassurance or intervention.101 An obvious example would be a woman that
unnecessarily undergoes chemoprevention as a result of a false-positive result of the DNA
sequencing screening. False-positive and false-negative results are not exclusive to BRCA1/2
mutation screening. But, considering the serious and often drastic preventive measures that may
follow from a false-positive result, the harm in subjecting oneself to a questionably beneficial
test seems to substantially any benefit. Unfortunately, no studies directly address these issues.102
Another potential adverse effect is emotional distress. Nelson’s study focused on nine
studies that assessed breast cancer risk assessment, genetic testing, and genetic counseling their
subsequent impact on distress measured as breast cancer worry, anxiety, or depression.103
According to Nelson, more studies showed decreased cancer worry or anxiety after risk assessment
and testing.104 There were mixed results as to depression.105 Distress varied according to whether
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studies evaluated risk assessment, genetic testing, or both.106 In four studies that evaluated risk
assessment, most measures of breast cancer worry, anxiety, and depression decreased, and only 1
measure of breast cancer worry increased.107 When genetic testing was evaluated, breast cancer
worry and anxiety increased, and results for depression were mixed. 108
Lastly, there are several adverse effects associated with interventions for women
identified as high risk by history, positive genetic test results, or both.109 Women with known
mutations typically undergo one to three annual breast cancer screen examinations. The four
most popular, intensive cancer screening methods are magnetic resonance imaging (MRI),
mammography, ultrasonography, and clinical breast examinations. Use of MRI, ultrasonography,
and mammography together had a sensitivity of 95%.110 Nelson did not identify any studies
describing the adverse effects of intensive cancer screening for breast or ovarian cancer.
However, her study did mention potential adverse effects such as inconvenience of frequent
examinations and procedures, exposure to ionizing radiation that could increase risk for breast
cancer, cost, harms resulting from false-positive finding and subsequent testing and biopsies, and
false reassurance for women who may have increased risks for developing cancer between
periodic cancer screening tests.111 Other serious adverse effects are associated with
chemoprevention and prophylactic surgery (mastectomy and oophorectomy), both of which may
follow as interventions for women identified as high risk by history, positive genetic test results,
or both.112
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In conclusion, Nelson’s study uncovered two important points. First, Nelson explained
that more information is needed about the impact of screening in the general population in order
to determine the appropriateness of risk assessment and testing for BRCA mutations in primary
care.113 While primary care physicians have a number of risk assessment tools at their disposal,
their effectiveness is not known among asymptomatic women in the general population.
Secondly, Nelson concluded that there are significant potential harms related to BRCA mutation
testing among women in the general population. Using these conclusions, the USPSTF issued its
recommendation, which are discussed below.
In its recommendation statement, the USPSTF made two significant recommendations.
First, the USPSTF recommended against routine referral for genetic counseling or routine BRCA
testing for women whose family history is not associated with an increased risk for deleterious
BRCA1/2 mutations.114 Second, the USPSTF recommended that women whose family history is
associated with an increased risk for deleterious mutations in BRCA1/2 genes be referred for
genetic counseling and evaluation for BRCA testing.115 In weighing the clinical utility of routine
BRCA1/2 mutation testing for women without certain specific family history patterns, the
USPSTF found that any benefit to routine screening or routine referral for genetic counseling
would be small or zero.116 As mentioned above, the prevalence of BRCA1/2 mutations among
average risk and moderate risk women is only .24% and .24% to 3.4%, respectively.117 These
numbers are too low to warrant a recommendation for routine screening. Moreover, the USPSTF
found substantial evidence regarding important adverse ethical, legal, and social consequences
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that could result from routine referral and testing of these women.118 The USPSTF estimated that
the magnitude of the potential harms associated with interventions such as prophylactic surgery,
chemoprevention, or intensive screening is small or greater.119 Thus, the USPSTF concluded that
the potential harms of routine referral for genetic counseling or BRCA testing in these women
outweigh the benefits.120 As to the second recommendation, the USPSTF found that women with
certain specific family history patterns would benefit from genetic counseling. The task force
believes that counseling will give these women an opportunity to make informed decisions about
testing and further prophylactic treatment.
B. Recommendations of Other Professional Medical Groups
Four other organizations have made recommendations on genetic susceptibility testing.
The American College of Medical Genetics (ACMG) recommends risk assessment and genetic
counseling before testing for BRCA1/2 mutations in individuals at increased risk, based on a
personal or family history of breast cancer, ovarian cancer, or both.121 The National
Comprehensive Cancer Network recommends offering genetic susceptibility testing to individuals
who meet the criteria for hereditary breast or ovarian cancer or both.122 The American Society of
Clinical Oncology recommends that genetic testing be offered when: 1) an individual has a
personal or family history that suggests a genetic cancer susceptibility; 2) the test can be
adequately interpreted and its results will influence diagnosis or management of the patient or
family members at risk for hereditary cancer.123 The American College of Obstetrician and
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Gynecologists Committee Opinion (ACOG) on breast and ovarian cancer screening, written in
2000, recommends offering BRCA mutation testing to families in which multiple family members
have had breast or ovarian cancer or in which a BRCA mutation has been found.124 The
recommendations of each of these groups are analogous to the USPSTF recommendations in that
they only recommend BRCA testing when the patient falls into a high-risk category.
In sum, there are five different professional medical organizations that recommend BRCA
testing only when a woman falls into a high-risk category. Despite this apparent plethora of
information for doctors and patients, these groups seem disconnected from the overall message.
The following section discusses issues related to doctor and patient use and understanding of
clinical guidelines for genetic predisposition screening.
IV. Problems Related to Physician and Patient Use and Understanding of Genetic
Screening for Cancer Susceptibility
A. Primary Care Physicians
The purpose of the USPSTF’s recommendations is to improve care by providing national
guidelines for doctors. It is often difficult for doctors to keep up with the most recent literature,
especially in areas beyond their specific area of concentration. Thus, the recommendations and
guidelines released by the USPSTF are important to catch doctors up on the latest procedures
and practices to promote more efficient and effective care. For example, when it comes to
susceptibility testing for diseases such as breast and ovarian cancer, interpretations of genetic
tests require sophisticated knowledge that many primary care providers may lack. In fact,
physician knowledge of genetics has been low in self-reported surveys and in direct

American College of Obstetricians and Gynecologists, Breast-Ovarian Cancer Screening. 75 INT’L J.
GYNAECOLOGY OBSTRETRICS 339, 340 (2000).
124

21

Lanza
assessment.125 Only 37% regularly read articles on genetic testing.126 Interestingly, despite the
USPSTF recommendation discussed above, 89% of physicians have indicated needs for clinical
guidelines for genetic testing for cancer susceptibility.127 Physicians also expressed concern for
insurance discrimination, confidentiality.128 Finally, most physicians believe that their
responsibilities include counseling patients about genetic testing, but only 51% have time to do
so.129 These numbers show not only that doctors recognize the importance of genetics regardless
of their field of medicine, but also that doctors feel they have inadequate resources to meet the
demands of their practice.
Although doctors seem to have serious concerns with respect to genetic testing, doctors
continue to order genetic tests and referrer patients for testing. One study has suggested that 60%
of primary care physicians have ordered genetic test, and 74% have referred a patient for
testing.130 There seems to be a serious disconnect between what doctors feel and do with respect
to genetic testing. Many factors are involved in whether physicians order tests, including patient
inquiry about testing, provider assessment of the probability of a patient’s carrying a mutation,
and practice environment.131 Referral for cancer susceptibility tests has been associated with
patient request and physicians receiving genetic test advertising.132
Understanding the issues related to physicians and their attitudes and practices concerning
genetic testing is important in the discussion of the USPSTF recommendations. Klitzman says
clinical guidelines for utilization of genetic testing are increasingly being developed, but it is
unclear how many physicians are aware of these guidelines, or in what specific areas they see
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themselves as needing training.133 The USPSTF, ACMG, and others cannot achieve their goal of
educating doctors and promoting efficient and effective health care if doctors are not even aware of
the guidelines or how to apply them. It is important that doctors are driven to ordering tests for the
right clinical reasons, and not by other uninformed motivations.
B. Patients
Recent developments in science and technology have captured the public consciousness.
With news coverage of advances in genetics, and direct-to-consumer (DTC) marketing of tests,
patients’ interest in testing will no doubt continue to grow.134 Despite a growing interest in
testing, patients still have serious misconceptions about testing and their risk for cancer
susceptibility. Women often overestimate their risks for breast cancer or BRCA mutations and
most women responding to surveys, including women at average and moderate risk, report a
strong desire for genetic testing even though only those at high risk would potentially benefit.135
Ultimately, the USPSTF hopes that its guidelines lead to better care for patients. But, as doctors,
rather than patients, are the targeted audience for its recommendation, it is unclear if patients
have any knowledge of the USPSTF guidelines. Perhaps the USPSTF needs to do more to
promote its recommendations and expand its targeted audience. Whether patients would heed the
advice of the USPSTF or even understand the guidelines and the technical reasoning behind the
recommendation is unclear.
V. Author’s Recommendation
In order to meet the growing demand of information regarding genetic testing for cancer
susceptibility, certain programs and initiatives need to be developed to educate doctors and
patients. Within the medical profession, organizations, such as the USPSTF, American College
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of Medical Genetics, and others, need to create educational programs for doctors, especially
primary care physicians who are often on the frontline in assessing risk for cancer susceptibility
among patients. For example, one recommendation is that practicing physicians should be
required to attend continuing education seminars on advancements in genetics once every five
years. Additionally, current medical students could be required to take multiple genetics classes
so they are prepared to meet the demand for information regarding cancer susceptibility once
they begin practicing medicine.
On the other side of the issue, in order to better educate patients, the USPSTF could push
for publication of its clinical guidelines for genetic predisposition testing in more widely
circulated streams of media and social media. Furthermore, it can be expected that information
passed on doctors will eventually trickle down to patients.
Conclusion
Practice and procedural guidelines provide an invaluable resource to physicians. In the
field of genetics, the recommendations of the USPSTF are especially important in guiding how
physicians tackle the issue of genetic testing cancer susceptibility. Armed with these
recommendations and the scientific data to support them, doctors can provide better care to their
patients. Studies have shown that the clinical utility of BRCA1/2 mutation testing is greatly
outweighed by the adverse effects of testing among women that do not belong to specific highrisk groups. Nevertheless, there is a gap between the recommendations and the actions of
physicians and patients. Hopefully, with the use of greater educational programs and resources
for physicians and greater outreach by the medical community to the general public, practices
can be improved to fall in line with the recommendations of the USPSTF.
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